WEKO3
-
RootNode
アイテム
Current progress and perspectives for human tumor immunotherapy
https://doi.org/10.15114/tr.41.1
https://doi.org/10.15114/tr.41.1e6ba0773-26e0-4c7e-bdf1-32e12acbaf80
名前 / ファイル | ライセンス | アクション |
---|---|---|
n004140934111.pdf (358.7 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-07-31 | |||||
タイトル | ||||||
タイトル | Current progress and perspectives for human tumor immunotherapy | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Tumor antigens | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Cancer vaccines | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | HSP | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Cross_presentation | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
ID登録 | ||||||
ID登録 | 10.15114/tr.41.1 | |||||
ID登録タイプ | JaLC | |||||
著者 |
Sato, Noriyuki
× Sato, Noriyuki× Hirohashi, Yoshihiko× Kamiguchi, Kenjiro× Ichimiya, Shingo× Sahara, Hiroeki× Hirata, Koichi× Tsukamoto, Taiji× Yamashita, Toshihiko× Torigoe, Toshihiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The investigation of human tumor immunotherapy has remarkably advanced in the past decade. In our laboratory, human tumor antigens and their HLA-A24-restricted immunogenic peptide epitopes were determined to develop therapeutic and prophylactic human cancer vaccines. Among these peptides, survivin 2B peptide derived from survivin, an inhibitor of apoptosis protein (IAP), is immunogenic in more than 50% of cancer patients with a wide variety of tumors, including colon, pancreas, lung, breast, urinary bladder and oral cancers. It is now under clinical trials, and with careful immunological monitoring we will finally be able to know if these vaccines can work clinically.To develop a potent clinical therapeutic protocol, the immunological tumor escape mechanism should be more thoroughly examined in human tumor materials. To this end, anti-HLA-A, B, and C allele-specific monoclonal antibody EMR8-5, which can be used in routine paraffin-embedded sections, was successfully established. Unexpectedly, our data indicated that a high percentage of human cancers, particularly breast and prostate cancers, lost HLA-class I molecules in their primary cancer tissues. We will discuss possibilities for resolution of this important old but yet new problem.Although recent evidence has been accumulating for an important role of the heat shock proteins (HSPs) as so-called danger signals in initiating innate immunity and consequently activating acquired immunity, the precise immunological basis for this phenomenon remains to be elucidated. Our study indicated that certain HSP-chaperoned immunogenic peptides, particularly HSP90, could efficiently enter the cross-priming pathway in dendritic cells. Interestingly, this cross-priming was TAP-independent and followed endocytic pathways. We also showed that HSP90-chaperoned peptide complexes could work as a potential tumor therapeutic vaccine in the HLA-A24 transgenic mouse model. | |||||
書誌情報 |
Tumor Research en : Tumor Research 巻 41, p. 1-13, 発行日 2006 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0041-4093 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Sapporo Medical University |